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AbstrAct:
Our current understanding of eukaryotic transcription has greatly benefited from 
use of small molecule inhibitors that have delineated multiple regulatory steps in 
site-specific initiation and elongation of RNA synthesis by multiple forms of RNA 
polymerase (RNAP). This class of “transcription” drugs is also of therapeutic interest 
and under evaluation in clinical trials. However, to date very few small molecules that 
directly abolish transcription have been identified, particularly those that act at the 
level of RNAP II initiation. Using a biochemical assay that measures transcription from 
recombinant, natural p53-responsive promoters and an artificial “super” promoter, 
we have identified three distinct small molecules that inhibit mRNA synthesis in 
vitro. Unexpectedly, these are kinase inhibitors, Hypericin, Rottlerin, and SP600125, 
with known substrates, which we find also strongly impair transcriptional initiation 
(IC50s = µM range) by targeting specific components of the RNAP II pre-initiation 
complex.  When  measured  before  and  during  transcription  in  vitro,  one  common 
target  of  inhibition  by  all  three  compounds  is  modification  of  the  TATA  Binding 
Protein (TBP) within the RNAP II holocomplex as it converts to an active transcribing 
enzyme. On this basis, by blocking the critical step of TBP modification, transcriptional 
initiation  is  effectively  abolished  even  on  structurally  distinct  core  promoters.
INtrODUctION
Eukaryotic RNA polymerase II (RNAP II) and 
basal transcription factors, such as TFIID, TFIIH, TFIIB, 
assemble into versatile pre-initiation complexes (PIC) on 
core promoters to regulate initiation of mRNA synthesis. 
Core promoters extend from ~-50 to + 50 bp relative to 
the start site of transcription at +1 and are composed of 
different combinations of specific DNA sequence motifs 
such as the TATA box, initiator (INR), TFIIB recognition 
element (BRE), downstream promoter element (DPE), 
and motif ten element (MTE). The exact combination 
of these DNA motifs can differentially modulate the 
assembly of PIC complexes, start site precision of 
initiation,  and  transcriptional  kinetics  from  specific 
promoters [1, 2]. After PIC assembly, multiple enzymatic 
processes must take place for productive mRNA synthesis 
to occur at the sequential steps of initiation, elongation, 
and RNA processing. Because transcription is dependent 
on diverse enzymatic reactions such as phosphorylation, 
ubiquitinylation, and acetylation, it is possible to inhibit 
mRNA  production  using  specific  pharmacological 
agents. For example, the transition from RNAP II pre-
initiation to initiation and finally elongation is influenced 
by  modifications  within  its  carboxyl-terminal  domain 
(CTD), which then functions as a platform for the ordered 
assembly of different pre-mRNA processing machinery 
[3]. Inhibition of cyclin-dependent kinases (Cdk) 
Cdk7 and Cdk9 abolishes RNAP II phosphorylation 
at  specific  serine  residues  in  the  CTD  and  prevents 
transcriptional elongation [4]. DRB (5,6-dichloro-1-b-D-
ribofuranosylbenzimidazole), which specifically inhibits 
CTD phosphorylation at serine 2, has been a particularly 
useful  reagent  in  the  transcription  field  because  it  has 
facilitated the dissection of multiple elongation steps and 
led to the identification of important transcription factors 
[5]. Advanced analogs of DRB such as Flavopiridol 
have also been developed and have shown promising Oncotarget 2011; 2:  18 - 28 19 www.impactjournals.com/oncotarget
therapeutic potential for several types of human cancer 
[6]. Known Cdk inhibitors act by competing for the ATP 
binding site on target kinases and have broad-spectrum 
substrate  specificities,  including  Cdk2/cyclin  E,  Cdk7/
cyclin H and Cdk9/cyclin T [7]. Interestingly, Flavopiridol 
and other drugs that affect basal transcriptional steps were 
initially thought to inhibit kinases involved in cell cycle 
progression or other signaling pathways [8-10].
It has been proposed that the transcription machinery 
itself may be a pivotal stress sensor that directs cell fate 
decisions by gauging the severity of damage and activating 
the p53 tumor suppressor pathway [11]. In this regard, 
several studies have shown that blocking global cellular 
mRNA synthesis in human cancer cell lines by the Cdk 
inhibitors Roscovitine (Seliciclib, CYC202), Flavopiridol, 
DRB, and H7 induces a strong stress response resulting 
in nuclear accumulation of p53, induction of certain p53 
target genes, and apoptosis [12-14]. On this basis, selective 
interference of transcription has become an active area 
of pursuit for the development of potential anti-tumor 
therapeutics [13]. Indeed, Flavopiridol and UCN-01 were 
the first Cdk inhibitors to be tested in clinical trials and 
have shown promising results, particularly in treating 
certain chronic leukemias or in combination therapy 
[14-16]. With the increasing availability of commercial 
drug libraries, it is now possible to identify novel small 
molecules that promote apoptosis through transcription 
interference. Our aim was to use in vitro transcription 
assays to identify new transcription inhibitors that act at a 
defined step in mRNA synthesis, initiation. To date, very 
few inhibitors of eukaryotic RNA initiation have been 
identified,  with  the  exception  of  the  mushroom  toxin, 
alpha-amanitin, a cyclic peptide that acts by binding 
directly to RNAP II and preventing its translocation [17].
In this study, we analyzed the impact of multiple 
kinase inhibitors on the activity of three recombinant 
DNA templates containing distinct core promoter 
structures: two natural p53-responsive promoters and an 
artificial “super” promoter using a well-characterized in 
vitro transcription assay. This enabled us to identify three 
compounds, Hypericin, Rottlerin, and SP600125 that are 
each strong inhibitors of RNA synthesis. In contrast to 
Figure 1. screening compound libraries by in vitro transcription (A) Structures of the p21, Fas/APO1, and SCP1 promoters used as 
in vitro transcription templates. Specific core promoter regulatory elements are defined in the text. (B) Diagram of the in vitro transcription 
assay showing: (1) Pre-initiation complex (PIC) formation and initiation of RNA synthesis, (2) RNAP II elongation and production of mRNA, 
(3) assay of in vitro synthesized RNA by annealing of radioactively labeled DNA primer, (4) primer extension and detection by PAGE. (C) 
Transcriptional analysis of p21, Fas/APO1, and SCP1 as a function of increasing amounts of DMSO. 
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DRB or Flavopiridol, drugs that abolish elongation by 
decreasing bulk cellular levels of phosphorylated CTD 
serine 2 phosphorylation, these compounds specifically 
inhibit early steps in transcription initiation by affecting 
enzymatically  engaged  RNAP  II/Promoter  complexes. 
A shared target of all three compounds is inhibition of 
modification of the TATA Binding Protein (TBP) within 
the RNAP II holocomplex as it converts to an actively 
transcribing form. In addition, we observe drug-specific 
effects on CTD phosphorylation of both bulk cellular and 
promoter-bound RNAP II. This reveals an unexpected 
role for diverse protein kinase inhibitors in directly 
regulating transcriptional initiation and expands their 
known substrate specificities to include essential factors 
that function on structurally distinct core promoters.
rEsULts
screening compound libraries by in vitro 
transcription 
To test the ability of a library of kinase inhibitors 
to affect RNAP II-dependent transcription, we employed 
an in vitro assay that uses nuclear protein extracts from 
human tissue culture cells [18], as a source of RNAP 
II and transcription components. These reactions were 
programmed with supercoiled plasmids containing 
recombinant promoters that drive expression of reporter 
genes. This assay can distinguish between two distinct 
steps in transcription, initiation of RNA synthesis by 
RNAP II and elongation of RNA transcripts. Although 
several inhibitors of elongation are known (DRB, 
Flavopiridol) [19], very few agents that impair initiation 
have been identified, except a-amanitin. For this reason, 
we specifically measured RNAP II-dependent initiation 
in our assays. The recombinant DNA templates we 
analyzed consisted of two natural human promoters, 
p21 and Fas/APO1, and one synthetic promoter, the 
Super Core Promoter (SCP1).  p21 and Fas/APO1 are 
physiologically important p53 target genes that regulate 
cell cycle arrest and apoptosis, respectively [20-22]. Both 
p21 and Fas/APO1 were previously characterized by in 
vitro transcription and can drive robust RNA synthesis in 
this assay [23]. Furthermore, p21 and Fas/APO1 represent 
two structurally distinct types of natural promoters (Figure 
1A). p21 contains multiple classic core promoter elements 
such as a TATA box, initiator (INR), and downstream 
promoter element (DPE). Whereas Fas/APO1 lacks these 
canonical elements but contains a critical NF-Y response 
element near the +1 start site of transcription. NF-Y is 
a bifunctional transcription factor that regulates basal 
expression of Fas/APO1 in vivo [23]. The SCP1 promoter 
is a synthetically designed chimeric promoter constructed 
Figure 2: A kinase inhibitor screen identified 4 cocktails that block in vitro transcription. (A) Diagram of the in vitro transcription 
drug screen using 80 kinase inhibitors from BIOMOL (BML-2832). The 80 compounds were mixed into 20 cocktails containing 4 drugs each 
at final concentrations of 50µM in the transcription reactions. (B) Four of the drug cocktails significantly reduced in vitro transcription of all 
three templates, p21, Fas/APO1, and SCP1, relative to controls.
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Figure 3: Identification of specific drugs that inhibit RNAP II-dependent initiation. Three active compounds within the drug 
cocktails were identified that effectively inhibited transcriptional initiation and are highlighted with red rectangles. In vitro transcription 
reactions were performed in duplicates. The compounds are Hypericin (from cocktail #7), Rottlerin (from cocktail #14), and SP600125 (from 
cocktail #16). 
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by using sequence motifs from viral as well as cellular 
genes [24]. We included the SCP1 template in all of our 
transcription reactions, containing either p21 or Fas/
APO1 plasmids, as a positive internal control because of 
its strong activity in vitro. Importantly, use of these three 
DNA templates allowed us to screen for compounds that 
could inhibit the initiation of RNAP II transcription from 
structurally diverse promoters. 
In the in vitro transcription assay, mRNA synthesis is 
detected by primer extension, in which purified transcripts 
are annealed to a short, 32P-labeled DNA primer followed 
by Reverse Transcriptase-mediated extension to generate 
transcripts of known length, and visualized by PAGE 
(Figure 1B). Due to the multiple steps involved in this 
assay, it is not well-suited for use in high-throughput 
screening of large compound libraries. However, this 
approach has multiple advantages that make it attractive to 
screen a small collection of compounds. For example, one 
can selectively analyze the effect of compounds or other 
therapeutics in targeting distinct steps in transcription, 
such as PIC assembly, initiation (up to 100 bp), elongation 
and termination. In the present study, we directly measured 
RNAP II-directed initiation only, which was independent 
of chromatin structure, nuclear localization, or other 
upstream processes that complicate the interpretation of 
cell-based assays, thus greatly simplifying our analyses. 
To begin, we tested the sensitivity of in vitro transcription 
to DMSO since drugs are commonly dissolved in this 
solvent. Activity from the three promoters was robust in 
buffers containing up to 4% DMSO (v/v) (Figure 1C), 
which set the limit for the volume of compound that could 
be added to each reaction.
Identification  of  specific  kinase  inhibitors  that 
directly impair transcriptional initiation
We screened 80 commercial kinase inhibitors 
(BIOMOL International, see Supplemental Table 1) for 
their activities towards early steps in transcription on 
the p21, Fas/APO1, and SCP1 promoters. To facilitate 
screening, the 80 kinase inhibitors were first combined 
into 20 cocktail mixes each containing four drugs. The 
4-drug cocktails were added (50µM final concentration) to 
the transcription reactions before initiating RNA synthesis 
with nucleotide triphosphates (NTPs) (Figure 2A). The 
resulting transcripts were measured by primer extension, 
followed by PAGE, and compared using a phosphoimager. 
Using  this  strategy,  we  identified  four  cocktail  mixes 
(C-7,  C-8,  C-14,  and  C-16)  that  significantly  reduced 
transcriptional activity from each of the three promoters 
(Figure 2B).
The four cocktail mixes were further investigated 
by testing each of the compounds individually. We 
observed that only a single compound from cocktails 
C-7, C-14, and C-16 significantly inhibited transcriptional 
activity (Figure 3). Interestingly, none of the individual 
compounds in cocktail 8 were able to reduce transcription, 
which suggests a requirement for combinatorial inhibition 
in this particular mix. The three active compounds 
identified using this strategy were Hypericin, Rottlerin, 
and SP600125. These three small molecules have 
not previously been implicated, to our knowledge, in 
blocking basal transcription initiation. Hypericin induces 
apoptosis in cancer cells and is a potent antiviral agent 
[25-27]. Hypericin has also been used as a photocytotoxic 
compound, becoming active towards other targets upon 
intense light activation. This drug has been shown to inhibit 
protein kinase C (PKC), irreversibly damage the sarco/
endoplasmic reticulum and other cellular membranes, 
decrease cellular pH, and inhibit mitochondrial function 
[27-29]. Rottlerin (mallotoxin) is considered to be a 
strong inhibitor of PKC delta but several studies have 
reported that it can inhibit other targets without affecting 
PKC delta [30-32]. SP600125 is a novel and selective 
inhibitor of c-Jun N-terminal kinase (JNK) (5). These 
three compounds have very different substrate targets, 
yet each can effectively impair RNAP II initiation on the 
structurally distinct promoters that we examined. 
We further characterized these compounds by 
analyzing their half maximal inhibitory concentrations 
(IC50) to measure their individual effectiveness of the 
drugs  towards  transcription,  specifically  using  the  p21 
promoter template. The approximate IC50 values were: 
Hypericin, 12.6µM; Rottlerin, 3.52µM; and SP600125, 
5.03µM (Figure 4). Hypericin has been reported to be an 
effective inhibitor of epidermal growth factor with IC50 
values between 0.37-8.7µM [25]. Our data demonstrate 
that photo-inactivated Hypericin can inhibit transcription 
at slightly higher concentrations. Rottlerin has been 
frequently used as a specific inhibitor of PKC delta and 
has been reported to have an IC50 of 3-6µM [31, 33]. 
Another study examining multiple compounds found that 
Rottlerin does not inhibit PKC delta but instead inhibits 
PRAK and MAPKAP-K2 potently, with IC50 values 
of  1.9µM  and  5.4µM,  respectively  [30].  Our  results 
suggest that Rottlerin inhibits RNAP II transcription 
initiation  with  comparable  specificity  as  that  towards 
its known substrates, PKC delta, MAPKAP-K2, and 
PRAK. SP600125, a well-characterized inhibitor of 
JNK, can block c-Jun phosphorylation in cells with an 
IC50 of 5–10 μM. However, biochemical assays using 
purified  components  produced  IC50  values  of  0.11μM 
[34]. SP600125 is an ATP competitor, thus the observed 
differences in IC50 values from biochemical and cell-
based assays most likely reflects high ATP levels in cells. 
We used non-limiting amounts of ATP in the in vitro 
transcription reactions and our observed IC50 of 5.03μM 
probably represents a more “in vivo” concentration. 
Effect of specific kinase inhibitors on components 
of the transcription initiation complexOncotarget 2011; 2:  18 - 28 23 www.impactjournals.com/oncotarget
Figure 4: Analysis of the half-maximal inhibitory concentration (IC50) for kinase inhibitors of transcription initiation. 
Increasing concentrations (0-160µM) of Hypericin, Rottlerin, and SP600125 were added individually to in vitro. transcription reactions using 
the p21 promoter template. Reactions were analyzed as described and quantified using a phosphoimager. 
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Known kinase inhibitors that interfere with 
transcription, such as Flavopridol and DRB, typically 
block phosphorylation of the RNAP II C-terminal domain 
(CTD), which abolishes elongation. We tested Hypericin, 
Rottlerin, and SP600125 for their ability to inhibit serine 2 
or serine 5 phosphorylation of the RNAP II-CTD in human 
colon cancer HCT116 cells. We found that each drug had 
relatively little effect on bulk, cellular RNAP II CTD 
phosphorylation compared to DRB (see Supplemental 
Data).  To  refine  this  analysis  and  explore  how  these 
compounds may inhibit transcription when RNAP II is 
actually assembled on a target promoter, we tested their 
individual activities towards several components of the 
initiation complex using immobilized DNA templates. 
In this assay, the transcriptional machinery in HeLa 
extracts is “recruited” to p21 promoter templates that are 
immobilized on magnetic beads, excess unbound protein 
is then washed from the beads leaving engaged RNAP II 
“pre-initiation” complexes on the promoters. Transcription 
is subsequently initiated by the addition of NTPs, which 
converts  the  RNAP  II  machinery  to  a  “post-initiation” 
phase (diagrammed in Figure 5A). Capturing these 
functionally distinct RNAP II complexes on immobilized 
p21 promoters enabled us to examine the effect of 
each kinase inhibitor on the protein composition and 
modification status of several transcription components 
by Western blotting using appropriate antibodies. As 
shown  in  Figure  5B,  nearly  equal  amounts  of  RNAP 
II were assembled and retained after NTP addition on 
promoters in the presence or absence of the each of the 
kinase inhibitors, with the exception of Hypericin which 
showed a slight decrease in bound RNAP II. Similarly, 
no effect of any drug was observed on TFIIB, a required 
initiation factor that interacts with the BRE core promoter 
element;  or  Cdk9,  a  kinase  that  is  required  for  RNAP 
II elongation through phosphorylation of CTD-serine 
2 and the target of inhibition by DRB and Flavopiridol 
[19]. Interestingly, only SP600125 demonstrated a clear 
inhibition of phosphorylation of promoter-bound RNAP 
II at both serine 2 and serine 5 within the CTD. Whether 
SP600125 inhibits distinct kinases that phosphorylate 
each residue or a single kinase that acts upstream of these 
events is unknown at present. One common feature of each 
of the three drugs is the striking loss of mobility shift of 
the promoter-bound TATA Binding Protein (TBP). In the 
absence of drug (DMSO lanes), TBP migrates as a single 
band when part of the pre-initiation complex (lane 1). 
However upon NTP addition, which activates transcription 
by RNAP II, bound TBP appears to undergo a series of 
post-translational modifications as indicated by a trailing 
shift to higher molecular weight species (compare lanes 
1 and 2). These are most likely phosphorylated isoforms 
because they are inhibited by each of the three drugs. Thus, 
a common target of inhibition by Hypericin, Rottlerin, 
Figure 5: Immobilized transcription and recruitment assay. (A) Diagram of the immobilized transcription and recruitment assay 
(see text for details). (B) HeLa nuclear extracts and p21 promoters immobilized on magnetic beads were mixed in the presence or absence of 
50µM Hypericin, Rottlerin, or SP600125. RNA synthesis was initiated with NTPs and RNAP II complexes captured during active transcription. 
Initiation complexes were then analyzed by Western blotting using the indicated antibodies to components of the initiation complex. In lane 1, 
NTPs were omitted in order to compare pre-initiation to transcriptionally active, post-initiation complexes. 
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and SP600125 is TBP modification within the RNAP II 
holocomplex as it converts to an active enzyme. On this 
basis, by blocking the critical step of TBP conversion, 
transcriptional initiation is effectively abolished. 
DIscUssION
Using an in vitro transcription assay, we examined 
the effect of 80 previously characterized kinase inhibitors 
specifically on the initiation of RNA synthesis by human 
RNAP II from three structurally diverse core promoters. 
This assay, although labor intensive, is unique in providing 
a  semi-purified  cell-free  system  in  which  to  directly 
analyze drug activity on components of the transcriptional 
machinery. To facilitate screening the library of 80 
commercially available kinase inhibitors, we initially 
tested drug cocktails containing combined compounds. 
We discovered four cocktails that demonstrated 
significant reduction in transcriptional activity and further 
characterized each compound separately. This led to 
the identification of three novel inhibitors of RNAP II-
dependent transcriptional initiation: Hypericin, Rottlerin, 
and SP600125. These three compounds are thought 
to have alternative targets and, in fact, many kinase 
inhibitors are pan-specific, yet they are routinely used to 
block “specific” enzymes. Thus, studies using Hypericin, 
Rottlerin, or SP600125 and many other protein kinase 
inhibitors (PKIs) are likely to have pleiotrophic effects, 
particularly in cell-based studies. It is therefore striking 
that novel and unexpected targets of these broad-spectrum 
PKIs could be identified in such a direct and defined assay 
as one that measures transcriptional initiation. 
We characterized the strength of inhibition towards 
transcription by calculating the IC50 for each compound. 
This revealed that the specific activity of these compounds 
was relatively strong. Rottlerin was the strongest inhibitor 
of  initiation,  with  an  IC50  of  approximately  3.52µM. 
The compounds SP600125 and Hypericin were also 
effective in the micromolar range, with IC50 values of 
5.03µM and 12.6µM, respectively. Previous reports using 
these compounds demonstrated their potential towards 
reducing transcription. For example, exposure of human 
Jurkat T-cells to Hypericin resulted in down-regulation 
of global mRNA synthesis, culminating in a strong, time-
dependent cytotoxicity [34]. Our finding that Hypericin 
directly targets components of the RNAP II transcription 
complex to impair initiation may provide mechanistic 
insight into this observation. In addition, SP600125 was 
reported to reduce mRNA expression of the COX-2 gene 
in cell-based studies, potentially by inhibiting JNK [35]. It 
is possible that down-regulation of COX-2 expression can 
be attributed to the ability of SP600125 to directly inhibit 
transcription complexes bound to the COX-2 promoter. 
Most kinase inhibitors that block transcription 
usually function by preventing global cellular 
phosphorylation of RNAP II at serine 2 within the 
CTD, which affects elongation rather than initiation. 
Interestingly, our experiments reveal that Hypericin, 
Rottlerin, and SP600125 have relatively low inhibitory 
activity towards CTD phosphorylation of global RNAP 
II (Figure S1). Only by analyzing phosphorylation of 
promoter-bound RNAP II initiation complexes using 
immobilized DNA templates were we able to detect 
blockage of RNAP II CTD phosphorylation at both serine 
2 and 5, specifically by SP600125. Using the immobilized 
assay, we also observed a shift in electrophoretic mobility 
(presumably  due  to  protein  modification)  of  promoter-
bound TBP upon addition of nucleotide triphosphates 
(NTPs) to initiate transcription. Surprisingly, conversion 
of TBP to transcription-dependent modified isoforms was 
completely blocked by each of the three compounds; the 
TBP modification disappears and looks exactly like TBP 
bound before transcription initiation. A previous study 
demonstrated that yeast TBP could be phosphorylated by 
CK2, which copurifies with the TFIID holocomplex and 
by DNA-dependent protein kinase (DNA-PK) [36-38]. 
Additional  studies  will  be  required  to  fully 
understand the mechanism of action of these compounds 
and their relevant kinase targets. It is noteworthy that 
the three compounds inhibit TBP phosphorylation from 
architecturally diverse promoters, revealing a requirement 
for TBP within the TFIID complex from both TATA box-
containing (p21 and SCP1) and TATA-less (Fas/APO1) 
promoters. The identification of these compounds adds 
to the limited toolbox available to scientists studying 
transcription regulation. Hopefully, they will aid in finding 
new mechanistic information and provide additional 
drugs beyond those currently used to study RNAP II 
transcription. In addition, analogues of these compounds 
may provide new therapeutic candidates to treat some 
types of human diseases. 
Many therapeutic drugs have been used to treat 
specific diseases without understanding their mechanism 
of action. In this regard, in vitro transcription analyses 
may be quite valuable, especially when adapted to a high-
throughput format, since this assay is highly sensitive 
and has been used extensively to decipher fundamental 
mechanisms of transcription from core promoter elements, 
activators, and repressors. Moreover, this versatile assay 
can  be  modified  to  assess  the  effects  of  chemical  and 
biological agents on transcription that is regulated by 
specific  activators  (i.e.  p53-dependent  transcription), 
repressors, or enzymatic complexes. In addition, any DNA 
template can be assembled into nucleosomal structures and 
used to assay the effect of compounds on such regulatory 
steps as protein-targeted chromatin remodeling, histone 
modification,  or  other  epigenetic  events  [18,  39,  40]. 
Consequently, the effect of small molecules or biologics 
on gene regulation can be analyzed at a very precise 
mechanistic level.
MAtErIALs AND MEtHODsOncotarget 2011; 2:  18 - 28 26 www.impactjournals.com/oncotarget
In vitro transcription assays
Nuclear protein extracts from HeLa cells were 
prepared as described (Dignam et al. 1983). Transcription 
reactions  included  10µl  (~5-6µg/µl)  HeLa  Nuclear 
Extract (HNE), 15µl HeLa Dialysis Buffer (HDB) (20mM 
Hepes-pH7.9, 50mM KCl, 1mM DTT, 0.2mM EDTA, 
10%  glycerol)  and  25µl  transcription  mix  (0.4mg/ml 
BSA, 20mM HEPES-pH 7.9, 70mM KCl, 3mM DTT, 
1.2mM NTPs, 1-3mM MgCl2, 0.5µl RNase inhibitor per 
reaction) and 500ng supercoiled plasmid DNA templates. 
For the drug inhibition screen, NTPs were omitted from 
the transcription mix and the PIC was allowed to form 
for 30min at room temperature before adding 2µl of NTP 
mix to start the reaction (final volumes were adjusted with 
HDB). Transcription reactions were incubated in a 30°C 
water bath. Reactions were stopped and processed using 
reagents from Zymo Research (RNA Clean-up Kit-5) by 
adding 200µl of RNA binding buffer, applying the mixture 
to columns, washing two times with wash buffer and then 
eluting with 8µl of RNAse-free water. 
Primer extension analyses
Primer extension was performed by adding 3µl of 
primer annealing mix (10mM Tris, 1mM EDTA, 1.25M 
KCl) to each reaction and heating at 75°C for 2-3 minutes 
in heating blocks. Reactions were removed from the heat 
blocks and allowed to slowly cool to about 37°C. This 
was followed by addition of 23µl reverse transcription 
mix (20mM Tris-HCl pH 8, 10mM MgCl2,  0.1mg/ml 
Actinomycin D, 5mM DTT, 0.33mM dNTP) and 0.5µl 
M-MLV Reverse Transcriptase (Promega) per reaction 
and incubation at 37°C for 1 hour. Final reactions were 
precipitated, washed with ethanol, and placed in a speedvac 
for 5 minutes. DNA pellets were each resuspended in 
10µl formamide with EDTA (1mM)/NaOH(0.1mM) (2:1) 
and heated to 95°C for 2-3 minutes followed by snap 
cooling on ice. Samples were electrophoresed through 
8%  polyacrylamide/TBE  gels  (SequaGel-8,  National 
Diagnostics). 
Immobilized DNA recruitment assay 
For transcription reactions using immobilized DNA 
templates, plasmids containing the p21 promoter were 
first linearized by restriction enzyme cleavage with NotI, 
followed by cleavage with a second restriction enzyme, 
EcoRI,  to  generate  sticky  ends  that  were  filled-in  by 
Klenow DNAP with biotinylated dATP and dUTP. After 
removal of excess nucleotides, the biotinylated fragments 
were incubated with streptavidin-coated magnetic beads 
(Dynal,  Invitrogen)  and  purified  from  un-biotinylated 
DNA using a magnet. The immobilized p21 templates 
(250 fmoles) were each incubated with HeLa nuclear 
extract and reagents similar to in vitro transcription as 
previously reported [23]. Protein complexes were allowed 
to form a PIC on the promoter followed by treatment 
with the drug compounds. Transcription was initiated by 
adding NTPs and active transcription complexes were 
subsequently captured.
Western blotting
Captured proteins from the recruitment assay were 
electrophoresed through 10% polyacrylamide/TBE gels 
and transferred to a nitrocellulose membrane. Immunoblots 
were probed using antibodies to P-Ser5 CTD (H14) and 
P-Ser2 CTD (H5) from Covance; and antibodies to RNAP 
II (sc-9001), TBP (sc-273), TFIIB (sc-225), and CDK9 
(sc-8338) from Santa Cruz Biotechnologies.
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